<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02168361</url>
  </required_header>
  <id_info>
    <org_study_id>CHC-21</org_study_id>
    <nct_id>NCT02168361</nct_id>
  </id_info>
  <brief_title>The SIM-SOF Trial for Hepatitis C</brief_title>
  <official_title>The SIM-SOF Trial: A Randomized Trial Comparing Simeprevir-Sofosbuvir Versus Peginterferon/Ribavirin/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype-1a-infected Patients With Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center For Hepatitis C, Atlanta, GA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center For Hepatitis C, Atlanta, GA</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized trial of Hepatitis C-genotype 1-infected patients with compensated cirrhosis
      comparing the standard of care (Peginterferon/Ribavirin/Sofosbuvir) versus the off-label
      combination of simeprevir+ sofosbuvir without Ribavirin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients can be treatment naive or prior null response to Peg/RBV, and must be genotype
      subtype 1a.

      Must have Child's Class A cirrhosis/compensated and no history of decompensation
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sustained Virologic Response 12 (SVR-12)</measure>
    <time_frame>At 12 weeks post treatment, if serum HCV RNA is undetected</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virologic Relapse</measure>
    <time_frame>At weeks 4 or 12 weeks post treatment, if serum HCV RNA becomes detectable</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Breakthrough</measure>
    <time_frame>Between first dose of medication and 12 weeks/end of therapy, if serum HCV RNA becomes detectable</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to week 24</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>From first dose of medication (week 1) through week 24 (12 weeks of therapy total and 12 weeks post-therapy follow-up period)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegylated Interferon Alfa-2b (1.5 ugm/kg/week subcutaneously) plus ribavirin (1000-1200 mg daily orally) plus sofosbuvir (400 mg daily) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simeprevir + Sofosbuvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(SIM-SOF) which is Simeprevir + Sofosbuvir for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon alfa-2b</intervention_name>
    <description>1.5 ugm/kg/week subcutaneously injected along with ribavirin and sofosbuvir for 12 weeks total</description>
    <arm_group_label>Standard</arm_group_label>
    <other_name>Pegintron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprevir</intervention_name>
    <description>150 mg daily orally along with pegylated interferon and sofosbuvir for a total of 12 weeks</description>
    <arm_group_label>Simeprevir + Sofosbuvir</arm_group_label>
    <other_name>Olysio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>1000-1200 mg daily divided twice daily for 12 weeks in combination with pegylated interferon and sofosbuvir</description>
    <arm_group_label>Standard</arm_group_label>
    <other_name>Ribavirin Ribasphere Ribapak</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>12 weeks of combination sofosbuvir and simeprevir</description>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_label>Simeprevir + Sofosbuvir</arm_group_label>
    <other_name>Sovaldi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic hepatitis c,

          -  cirrhosis biopsy-proven, or via fibrotest,

          -  CPT score less than 7,

          -  genotype 1a,

          -  INR 2.3 or less,

          -  serum albumin greater than 2.7 gm/dL,

          -  total bilirubin less than 3 gm/dL,

          -  platelet count 50,000 per cubic milliliter or more

          -  GFR &gt;50 ml/min

        Exclusion Criteria:

          -  non genotype 1a,

          -  history of CPT class B or C or decompensation or history of same,

          -  HIV or HBV coinfection,

          -  prior treatment with boceprevir, telaprevir or any other direct acting antiviral
             agent,

          -  uncontrolled psychiatric or cardiopulmonary disorders,

          -  planning pregnancy or unwilling/unable to practice contraception
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian L Pearlman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Hepatitis C</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Hepatitis C</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 19, 2014</lastchanged_date>
  <firstreceived_date>June 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
